WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor

  • Authors:
    • Leila C.A. Cardoso
    • Kelly R.L. De Souza
    • Adriana Helena De O. Reis
    • Raissa  Coelho Andrade
    • Alberto C. Britto
    • Maria A.F.D. De Lima
    • Anna  C.E. Dos Santos
    • Paulo S. De Faria
    • Sima Ferman
    • Héctor N. Seuánez
    • Fernando R. Vargas
  • View Affiliations

  • Published online on: October 19, 2012     https://doi.org/10.3892/or.2012.2096
  • Pages: 315-320
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Wilms' tumor (WT) is a heterogeneous neoplasia characterized by a number of genetic abnormalities, involving tumor suppressor genes, oncogenes and genes related to the Wnt signaling pathway. Somatic biallelic inactivation of WT1 is observed in 5-10% of sporadic WT. Somatic mutations in exon 3 of CTNNB1, which encodes β-catenin, were initially observed in 15% of WT. WTX encodes a protein that negatively regulates the Wnt/β-catenin signaling pathway and mediates the binding of WT1. In this study, we screened germline and somatic mutations in selected regions of WT1, WTX and CTNNB1 in 43 WT patients. Mutation analysis of WT1 identified two single-nucleotide polymorphisms, one recurrent nonsense mutation (p.R458X) in a patient with proteinuria but without genitourinary findings of Denys-Drash syndrome (DDS) and one novel missense mutation, p.C428Y, in a patient with Denys-Drash syndrome phenotype. WT1 SNP rs16754A>G (R369R) was observed in 17/43 patients, and was not associated with significant difference in age at diagnosis distribution, or with 60-month overall survival rate. WTX mutation analysis identified five sequence variations, two synonymous substitutions (p.Q1019Q and p.D379D), a non-synonymous mutation (p.F159L), one frameshift mutation (p.157X) and a novel missense mutation, p.R560W. Two sequence variations in CTNNB1 were identified, p.T41A and p.S45C. Overall survival of bilateral cases was significantly lower (p=0.005). No difference was observed when survival was analyzed among patients with WT1 or with WTX mutations. On the other hand, the survival of two patients with the CTNNB1 p.T41A mutation was significantly lower (p=0.000517) than the average.

Introduction

Wilms’ tumor (WT) is a heterogeneous neoplasia characterized by several genetic and epigenetic abnormalities, involving tumor suppressor genes, oncogenes and genes related to the Wnt signaling pathway. The incidence of WT is 1/10,000 and bilateral presentation is observed in 10% of affected individuals. In approximately 1–2% of WT, recurrence occurs in the family (1).

The WT1 gene is an essential regulator of kidney development, critical to the survival and subsequent differentiation of kidney cells (2). The WT1 somatic, biallelic inactivation is seen in 5–10% of sporadic WT (1). The WT1 protein contains an amino-terminal transactivator and a carboxyl-terminal DNA-binding domain consisting of four zinc fingers. Alternative WT1 splicing results in four different isoforms of the protein, and the most abundant isoform (+KTS) is generated by insertion of amino acids lysine, threonine and serine (KTS), coded by exons 9 and 10 (36). Exon 9 represents an important target for germline mutations associated with Denys-Drash syndrome (DDS), and specific constitutional point mutations affect the properties of WT1 to bind with EGR1 (early growth response 1) consensus sequence (7).

Mutations in exon 3 of the CTNNB1 gene, which encodes β-catenin, were initially observed in 15% of tumor samples from WT patients (8). The β-catenin N-terminal region contains consensus phosphorylation sites for the serine/threonine kinase GSK-3β (glycogen synthase kinase 3β) protein, whose function is to phosphorylate β-catenin at multiple sites (Ser33, Ser37, Thr41 and Ser45). In the absence of signs of growth and differentiation, this phosphorylation results in β-catenin degradation mediated by ubiquitin (9,10). β-catenin stabilization in the nucleus activates the Wnt signaling pathway mediated by β-catenin/TCF (11), leading to the deregulation of β-catenin signaling, which is critical for the development of various malignancies, including WT (8).

Rivera et al(2) identified another gene, WTX, found inactivated in one third of the studied WT samples. The WTX protein forms a complex with β-catenin, APC, and other proteins to negatively regulate the Wnt/β-catenin signaling pathway, leading to the degradation of β-catenin (12). Rivera et al(13) showed that WTX shuttles between the cytoplasm and the nucleus, and mediates the binding of WT1, modulating its activity. Mutations in WTX and WT1 were initially thought to be mutually exclusive, while most mutations observed in CTNNB1 coincided with WT1 mutations (2).

In the present study, we screened germline and somatic mutations in the WT1 exons 8, 9 and 10, the WTX coding region and the CTNNB1 exon 3 in 43 WT patients.

Materials and methods

Patients

This study involved 43 patients with documented WT. All tumor samples were collected following neoadjuvant chemotherapy. This study was approved by the local ethics committee and the parents or tutors of all participant patients signed an informed consent.

DNA extraction

DNA extraction from peripheral blood and fresh tumor samples followed procedures established by Miller et al(14) and Sambrook et al(15).

Sequencing of WT1, WTX and CTNNB1

Blood and fresh tumor DNA samples were screened for WT1, WTX and CTNNB1 mutations with previously reported primers (2). PCR reactions contained 5 pmol of forward and reverse primers (Prodimol), 1 μm dNTPs (Life Technologies), 0.9 mM MgCl2, 10 mM Tris-HCl (pH 8.0), 25 μM KCl, 1 U Taq DNA polymerase (Life Technologies) and 100 ng of DNA in a 25 μl final volume. PCR conditions for WT1 exons 8, 9 and 10 assay consisted of 94°C for 5 min, 35 cycles at 94°C for 30 sec, 58°C for 30 sec and 72°C for 30 sec and 72°C for 7 min. PCR conditions for WTX exon 2 assay consisted of 94°C for 5 min, 35 ‘step down’ cycles at 94°C for 30 sec, 66°C (decreasing 0.3°C per cycle) for 30 sec and 72°C for 30 sec and 72°C for 7 min. Finally, CTNNB1 exon 3 amplification conditions were 94°C for 5 min, 35 ‘step down’ cycles at 94°C for 30 sec, 60°C (decreasing 0.2°C per cycle) for 30 sec, 72°C for 30 sec and 72°C for 7 min. PCR products were purified using the GFX™ PCR DNA and Gel Band Purification kit (GE Healthcare) and were subjected to nucleotide sequencing using BigDye v3.1 (Life Technologies). DNA samples and reference sequences (NG_009272 for WT1; NG_021345 for WTX; and NG_013302.1 for CTNNB1) (16) were aligned and compared to identify homozygous and heterozygous nucleotide positions using ChromasPro v. 1.41 and MEGA 5 software.

Statistical analysis

Kaplan-Meier curves were used to estimate 60-month survival rates and overall survival. The Mann-Whitney U test was used to compare age at diagnosis.

Results

Our sample consisted of 43 unrelated patients, 18 females and 25 males, diagnosed with WT. Bilateral disease was diagnosed in nine patients. WT mean age at diagnosis was 43 months for the whole sample (ranging from 4 to 137 months) and 32 months for bilateral cases only. Five patients also presented major phenotypic abnormalities: one with Beckwith-Wiedemann syndrome, one with hemihypertrophy, two with non-syndromic macrosomia and one with Denys-Drash syndrome. Table I shows clinical, histopathological and molecular data of all patients.

Table I

WT1, WTX and CTNNB1 mutations, histopathology of the tumors, and patient clinical data.

Table I

WT1, WTX and CTNNB1 mutations, histopathology of the tumors, and patient clinical data.

PatientsGenderLateralityHistopathologyDx ageWT1 exons 8, 9, 10WTX exon 2CTNNB1 exon 3Phenotype
7FUTri44rs16754 (B) Hemihypertrophy
8MBILNR6rs16754 (B)
9FUTri48rs16754 (B)
10FUTri10rs2234593 (B)
11MUBl136rs16754rs34677493 + rs61730681
13FUEp62rs2234593
14MUEp59rs16754
16MBDA29rs16754
18MUFA36R560W
19FUTri48rs61730681 (LOH)
21FUBl4rs61730681 (T, het)
22FUTri28T41A (T)Macrosomia
23MUFA57rs16754rs61730681
24FUTri13rs150075206 + rs61730681 (het)
25MUTri.42rs16754
27MBTri, PLNR61T41A (T)
28MUTri67rs16754 (B)
32FUBl7rs16754 (T)
34FUTri35rs61730681 (LOH)
35MUTri47rs16754 + rs2234593Beckwith-Wiedemann syndrome
36MUBl, DA32rs16754 (T)
37MUTri47S45C (T)
38FUBl/Ep, PLNR19rs16754 (T)Macrosomia
39MUTri28rs16754 (B)
40MUTri28g.17896insT, c.439insT p.157X (T)
41MUBl25rs16754 + R458XProteinuria
42MUSt56rs16754 (B) + rs2234593 (B)
43FUTri12rs16754 + rs2234593
44FBNA12C428Y (B)Denys-Drash syndrome

[i] NA, not available; M, male; F, female; Dx age, age at diagnosis (months); Tri, triphasic; Bl, blastemal; Ep, epithelial; St, stromal; DA, diffuse anaplasia; FA, focal anaplasia; PLNR, perilobar nefrogenic rests; ILNR, intralobar nephrogenic rests; (B), blood sample only; (T), tumor sample only; (LOH), loss of heterozygosis; (het), heterozygosis.

Mutation analysis of WT1 exons 8, 9 and 10 identified four sequence variants, namely, two single-nucleotide polymorphisms (SNPs), one novel missense mutation and one nonsense mutation. The synonymous sequence variant, SNP rs16754 (p.R369R), located at exon 8, was the most frequent mutation, having been observed in 17 patients. With the exception of case 7, all blood samples were heterozygous for this SNP, and no loss of heterozygosity (LOH) was observed in the available tumors. The only possible case of LOH was patient 38, whose tumor sample showed this variation in a homozygous (or hemizygous) state, but no blood sample was available from this patient. The second most frequent sequence variant, located at intron 9, was SNP rs2234593, observed in five patients. In three of these patients (patients 13, 35 and 43) blood and tumor samples were studied and did not show LOH. The novel missense mutation, p.C428Y (g.47820G>A; c.1283G>A) (Fig. 1A), was observed in heterozygosis in patient 44, a female patient with bilateral WT diagnosed at 12 months and clinical findings of Denys-Drash syndrome. Finally, patient 41 presented a nonsense g.48510C>T (c.1372C>T) transition, resulting in the replacement of an arginine for a stop codon (p.R458X) (Fig. 1B). This mutation was observed in heterozygosis in both blood and tumor samples. This male patient developed unilateral blastematous WT diagnosed at 25 months and proteinuria without other clinical findings of Denys-Drash syndrome.

Analysis of WTX exon 2 identified five sequence variants, two synonymous substitutions (rs61730681 and rs150075206), a non-synonymous mutation (rs34677493), a novel missense mutation and one frameshift mutation. SNP rs61730681 (p.Q1019Q) was observed in four female and two male patients, and LOH was observed in two of the four female carriers. SNP rs150075206 (p.D379D) and the non-synonymous mutation rs34677493 (p.F159L) were observed, respectively, in one female and one male patient, in both cases in association with SNP rs61730681. The novel missense mutation p.R560W, resulting from a C>T transition at position g.19136 (c.1678C>T) (Fig. 1C), was identified in hemizygosis in both blood and tumor samples of one male patient (patient 18), whose unilateral tumor showed focal anaplasia. Mutation g.17896insT (c.439insT), resulting in a frameshift and subsequent stop codon in the protein (p.157X) (Fig. 1D) was observed in the tumor sample of one male patient.

Two sequence variants in the CTNNB1 gene were identified in three patients, in all cases in a heterozygous state in the tumor samples. Sequence variation rs121913409 predicts the frequently described missense mutation p.S45C and was observed in one patient (patient 37). Variation rs121913412, predictive of missense mutation p.T41A, was observed in two patients (patients 22 and 27).

The overall 60-month survival rate for the whole sample was approximately 80%. Overall survival of bilateral cases was significantly lower (P=0.005) (Fig. 2A). No difference was observed when survival was analyzed among patients with WT1 mutations (P=0.778) (Fig. 2B), or in patients with WTX mutations (P=0.594) (Fig. 2C). On the other hand, survival of patients 22 and 27, carriers of the p.T41A mutation in CTNNB1, was significantly lower (P=0.000517) than the average (Fig. 2D). Overall survival of WT1 rs16754 carriers did not differ from the rest of the sample (P=0.561) and age at diagnosis did not differ between carriers and non-carriers of this sequence variant (P=0.817; data not shown).

Discussion

In the present study we screened for mutations in selected regions of WT1, WTX and CTNNB1 in 43 WT patients.

In WT1, rs16754A>G, predictive of the synonymous mutation p.R369R, was the most frequently observed sequence variant (17/43 patients). No LOH was observed in 8/17 patients whose blood and tumor samples were analyzed. According to Milani et al(17), rs16754 corresponds to a cis-acting genetic variation regulating WT1 expression levels. This SNP has been associated with better overall survival in pediatric acute myeloid leukemia patients, and among rs16754 carriers, an increased expression of WT1 mRNA was observed (18). In our sample, allele rs16754G was not associated with differential age at diagnosis (P=0.817), or overall survival (P=0.561) among carriers.

Sequence variation WT1 rs2234593 was present in five patients and in three of these no LOH was observed. This intronic variant, apparently, does not alter WT1 splicing sites (19).

The nonsense mutation p.R458X (p.R390X) was observed in one male patient with unilateral WT. This patient also had proteinuria and did not present genitourinary anomalies. This mutation has been frequently described in patients with DDS, and in at least one case of Frasier syndrome (20,21). Royer-Pokora et al(20) described three new cases of the WT1 p.R390X nonsense mutation, and reviewed eight other cases from the literature (2225), and observed that genitourinary anomalies were not present in 3/10 patients with p.R390X (20). Little et al(26) also described two female WT patients with p.R390X and without genitourinary anomalies. Shibata et al(25) studied seven cases of WT with rhabdomyogenic components (fetal rhabdomyogenic nephroblastoma), and found five cases with the p.R390X mutation. Corbin et al(27) observed the p.R390X mutation in a homozygous state in a tumor sample of one DDS patient who also presented the CTNNB1 p.T41A mutation in a heterozygous state.

The missense WT1 p.C428Y (g.47820G>A; c.1283G>A;) mutation described in this study was observed in heterozygosis in a female patient with bilateral WT diagnosed at age 12 months. This patient had genitourinary anomalies, and developed early-onset proteinuria and end-stage renal disease. Another missense mutation in the same protein residue, p.C428G, has previously been reported. This mutation changes a cysteine residue important for the coordination of the zinc atom in the zinc finger domain (28).

Sixty-month overall survival among carriers of all WT1 mutations in our sample did not differ from global overall survival, a finding that was also observed by Royer-Pokora et al(29).

Five sequence variants were detected in WTX, two synonymous mutations (rs61730681; p.Q1019Q and rs150075206; p.D379D), two non-synonymous mutations (rs34677493; p.F159L and p.R560W) and one frameshift mutation. With the exception of p.R560W, all other WTX mutations observed in our patients had been previously identified by Rivera et al(2).

Transition c.1678C>T, predictive of undescribed missense mutation p.R560W, was observed in one male patient with unilateral WT and focal anaplasia. Corbin et al(27) observed another WTX missense mutation, p.T429I, in a WT patient who also presented anaplasia. Germline mutations in WTX were described in X-linked dominant osteopathia striata with cranial sclerosis (OSCS) (30), a disease not associated with WT risk. To the best of our knowledge, the WTX p.R560W mutation has not been previously described among WT (27, 3137) or OSCS (30,38) patients.

In our sample, 60-month overall survival among carriers of all WTX mutations did not differ from global overall survival (P=0.594), as observed by Wegert et al(32).

CTNNB1 exon 3 sequencing showed two previously well-known missense mutations (8,39,40) in three patients of our sample, all in heterozygosis: p.T41A in two patients and p.S45C in one patient. These somatic mutations remove a major phosphorylation site for GSK-3β, leading to the stabilization of β-catenin, and they exert a dominant effect at the level of the β-catenin/TCF-mediated transcription; therefore, these mutations may be associated with the development and/or survival of WT (8,39). Notably, the two carries of the p.T41A mutation showed a significantly lower overall survival rate (P= 0.000517) than the rest of the sample. In spite of the small number of p.T41A carriers in our group of patients (two individuals), we could not find an association of this somatic mutation with poorer survival rate among WT patients in the literature.

Additional studies of the impact of WTX mutations are essential to better understand the reasons why only somatic, and not germline mutations in this gene result in WT. Also, the interaction of the WT1, WTX and CTNNB1 genes within the context of the Wnt signaling pathway, seems to be critical for the development and survival of various malignancies, including WT.

Acknowledgements

This study was supported by Conselho Nacional de Desenvolvimento Científico (CNPq) grants 401966/2010-0, 476808/2010-3, 573806/2008-0 and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) E26/170.026/2008.

References

1 

Dome JS and Huff V: Wilms Tumor Overview. GeneReviews. Pagon RA, Bird TD, Dolan CB and Stephans K: University of Washington; Seattle: 2011

2 

Rivera MN, Kim WJ, Wells J, et al: An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 315:642–645. 2007. View Article : Google Scholar : PubMed/NCBI

3 

Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM and Housman DE: Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci. 88:9618–9622. 1991. View Article : Google Scholar : PubMed/NCBI

4 

Lamond AI: RNA processing. Wilms’ tumour - the splicing connection? Curr Biol. 5:862–865. 1995.

5 

Wells J, Rivera MN, Kim WJ, Starbuck K and Haber DA: The predominant WT1 isoform (+KTS) encodes a DNA binding protein targeting the planar cell polarity gene Scribble in renal podocytes. Mol Cancer Res. 8:975–985. 2010.

6 

Huff V: Wilms’ tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nature. 11:111–121. 2011.

7 

Pelletier J, Bruening W, Kashtan CE, et al: Germline mutations in the Wilms’ tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell. 67:437–447. 1991.

8 

Koesters R, Ridder R, Kopp-Schneider AK, et al: Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms’ tumors. J Cancer Res. 59:3880–3882. 1999.

9 

Maeda O, Usami N, Kondo M, et al: Plakoglobin (γ-catenin) has TCF/LEF family - dependent transcriptional activity in beta-catenin-deficient cell line. Oncogene. 23:964–972. 2004.

10 

Oloumi A, McPhee T and Dedhar S: Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochim Biophys Acta. 1691:1–15. 2004. View Article : Google Scholar : PubMed/NCBI

11 

Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI

12 

Major MB, Camp ND, Berndt JD, et al: Wilms tumor supressor WTX negatively regulates Wnt/β-catenin signaling. Science. 316:1043–1046. 2007.

13 

Rivera MN, Kim WJ, Wells J, Stone A, et al: The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc Natl Acad Sci USA. 106:8338–8343. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Miller SA, Dykes DD and Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:12151988. View Article : Google Scholar : PubMed/NCBI

15 

Sambrook J, Fritsch EF and Maniatis T: Molecular Cloning: A Laboratory Manual. 2nd edition. Cold Spring Harbor; New York: 1989

16 

Nacional Center for Biotechnology Information. http://www.ncbi.nlm.nih.gov/:urisimplehttp://www.ncbi.nlm.nih.gov/. Accessed April 14, 2012

17 

Milani L, Gupta M, Andersen M, et al: Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells. Nucleic Acids Res. 35:e34–e43. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Ho PA, Kuhn J, Gerbing RB, et al: WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children’s oncology group. J Clin Oncol. 29:704–711. 2011.PubMed/NCBI

19 

Splice-Site Analyzer Tool. Genome Bioinformatics group of University of California Santa Cruz: Splice-Site analyzer tool. http://ibis.tau.ac.il/ssat/SpliceSiteFrame.htmurisimplehttp://ibis.tau.ac.il/ssat/SpliceSiteFrame.htm. Accessed January 20, 2012

20 

Royer-Pokora B, Beier M, Henzler M, Alan R, Schumacher V, Weirich A and Huff V: Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development. Am J Med Genet A. 127:249–257. 2004.

21 

Kohsaka T, Tagawa M, Takekoshi Y, Yanagisawa H, Tadokoro K and Yamada M: Exon 9 mutations in the WT1 gene, without influencing KTS splice isoforms, are also responsible for Frasier syndrome. Hum Mutat. 14:466–470. 1999.PubMed/NCBI

22 

Little MH, Prosser J, Condie A, Smith PJ, Van Heyningen V and Hastie ND: Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci USA. 89:4791–4795. 1992. View Article : Google Scholar : PubMed/NCBI

23 

Schumacher V, Schneider S, Figge A, et al: Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci USA. 94:3972–3977. 1997. View Article : Google Scholar : PubMed/NCBI

24 

Maiti S, Alam R, Amos CI and Huff V: Frequent association of β-catenin and WT1 mutations in Wilms tumors. Cancer Res. 60:6288–6292. 2000.

25 

Shibata R, Hashiguchi A, Sakamoto J, Yamada T, Umezawa A and Hata J: Correlation between a specific Wilms tumour suppressor gene (WT1) mutation and the histological findings in Wilms tumour (WT). J Med Genet. 39:e832002. View Article : Google Scholar : PubMed/NCBI

26 

Little SE, Hanks SP, King-Underwood L, et al: Frequency and heritability of WT1 mutations in nonsyndromic Wilms’ tumor patients: a UK Children’s Cancer Study Group Study. J Clin Oncol. 22:4140–4146. 2004.PubMed/NCBI

27 

Corbin M, de Reyniès A, Rickman DS, et al: WNT/β-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries? Genes Chromosomes Cancer. 48:816–827. 2009.

28 

Little MH, Williamson KA, Mannens M, Kelsey A, Gosden C, Hastie ND and van Heyningen V: Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion. Hum Mol Genet. 2:259–264. 1993.

29 

Royer-Pokora B, Weirich A, Schumacher V, et al: Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein β1 gene CTNNB1 for patients with Wilms tumors. Results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology. Cancer. 113:1080–1089. 2008. View Article : Google Scholar : PubMed/NCBI

30 

Jenkins ZA, van Kogelenberg M, Morgan T, et al: Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet. 41:95–100. 2009. View Article : Google Scholar : PubMed/NCBI

31 

Perotti D, Gamba B, Sardella M, et al: Functional inactivation of the WTX gene is not a frequent event in Wilms’ tumors. Oncogene. 27:4625–4632. 2008.PubMed/NCBI

32 

Wegert J, Wittmann S, Leuschner I, Geissinger E, Graf N and Gessler M: WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes Chromosomes Cancer. 48:1102–1111. 2009. View Article : Google Scholar : PubMed/NCBI

33 

Ruteshouser EC, Robinson SM and Huff V: Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer. 47:461–470. 2008.PubMed/NCBI

34 

Fukuzawa R, Anaka MR, Weeks RJ, Morison IM and Reeve AE: Canonical WNT signaling determines lineage specificity in Wilms tumour. Oncogene. 28:1063–1075. 2009. View Article : Google Scholar : PubMed/NCBI

35 

Fukuzawa R, Holman SK, Chow CW, Savarirayan R, Reeve AE and Robertson SP: WTX mutations can occur both early and late in the pathogenesis of Wilms tumour. J Med Genet. 47:791–794. 2010. View Article : Google Scholar : PubMed/NCBI

36 

Haruta M, Arai Y, Watanabe N, et al: Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children. Cancer Sci. 103:1129–1135. 2012. View Article : Google Scholar : PubMed/NCBI

37 

Scott RH, Murray A, Baskcomb L, Turnbull C, et al: Stratification of Wilms tumor by genetic and epigenetic analysis. Oncotarget. 3:327–335. 2012.PubMed/NCBI

38 

Perdu B, Lakeman P, Mortier G, Koenig R, Lachmeijer A and Van Hul W: Two novel WTX mutations underscore the unpredictability of male survival in osteopathia striata with cranial sclerosis. Clin Genet. 80:383–388. 2010.

39 

Li CM, Kim CE, Margolin AA, Guo M, et al: CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant Wilm’s tumors. Am J Pathol. 165:1943–1953. 2004.

40 

Uschkereit C, Perez N, de Torres C, Küff M, Mora J and Royer-Pokora B: Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation. J Med Genet. 44:393–396. 2007.

Related Articles

Journal Cover

January 2013
Volume 29 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Cardoso, L.C., De Souza, K.R., De O. Reis, A.H., Andrade, R.C., Britto , A.C., De Lima, M.A. ... Vargas, F.R. (2013). WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor. Oncology Reports, 29, 315-320. https://doi.org/10.3892/or.2012.2096
MLA
Cardoso, L. C., De Souza, K. R., De O. Reis, A. H., Andrade, R. C., Britto , A. C., De Lima, M. A., Dos Santos, A. C., De Faria, P. S., Ferman, S., Seuánez, H. N., Vargas, F. R."WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor". Oncology Reports 29.1 (2013): 315-320.
Chicago
Cardoso, L. C., De Souza, K. R., De O. Reis, A. H., Andrade, R. C., Britto , A. C., De Lima, M. A., Dos Santos, A. C., De Faria, P. S., Ferman, S., Seuánez, H. N., Vargas, F. R."WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor". Oncology Reports 29, no. 1 (2013): 315-320. https://doi.org/10.3892/or.2012.2096